/ Not yet recruitingNot Applicable A randomized, double-blind, placebo-controlled dose selection study with two RP 01 formulations evaluating anti-IgE immunotherapy in allergic patients
A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients
The purpose of the study is to evaluate safety and efficacy of three doses and two dosing regimens of RP01 as an anti-IgE immunotherapy in allergic patients.
100 Clinical Results associated with Resistentia Pharmaceuticals AB
0 Patents (Medical) associated with Resistentia Pharmaceuticals AB
100 Deals associated with Resistentia Pharmaceuticals AB
100 Translational Medicine associated with Resistentia Pharmaceuticals AB